Picture of Bioventus logo

BVS Bioventus Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapValue Trap

Annual income statement for Bioventus, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUSPROSPECTUSPROSPECTUS10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue292319340321431
Cost of Revenue
Gross Profit210235249234303
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses264294312296421
Operating Profit2825.528.225.49.9
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes8.666.119.6915.97.62
Provision for Income Taxes
Net Income After Taxes9.444.448.1114.79.59
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income0.558-12.26.8516.419.4
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-7.25-18-0.6594.3819.4
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS0.1410.0260.1660.2071.04
Dividends per Share

Or unlock with your email

Or unlock with your email